Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 8/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.41 |
| ▸ | FAP | Q12884 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6871695 | 0.98 | EPHX2 (0.58) | EPHX2NPSR1KDM4EPOLBDPP4 | |
| SCHEMBL18845118 | 0.98 | EPHX2 (0.62) | EPHX2NPSR1KDM4EPOLBDPP4 | |
| SCHEMBL2411177 | 0.98 | EPHX2 (0.62) | EPHX2NPSR1KDM4EPOLBDPP4 | |
| Hydrochloric Acid SCHEMBL75462 | 0.96 | EPHX2 (0.61) | EPHX2NPSR1KDM4EPOLBDPP4 | |
| SCHEMBL7440501 | 0.96 | EPHX2 (0.55) | EPHX2NPSR1KDM4EPOLBDPP4 | |
| Hydrochloric Acid SCHEMBL7131992 | 0.92 | EPHX2 (0.57) | EPHX2NPSR1KDM4EPOLBDPP4 | |
| SCHEMBL4450020 | 0.91 | — | — | |
| Hydrochloric Acid SCHEMBL76321 | 0.89 | EPHX2 (0.47) | EPHX2KDM4EDPP4DPP7MEN1 | |
| Hydrochloric Acid SCHEMBL7134822 | 0.86 | EPHX2 (0.51) | EPHX2NPSR1KDM4EPOLBDPP4 | |
| SCHEMBL23165798 | 0.83 | EPHX2 (0.43) | EPHX2KDM4EPOLBDPP4DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250235462-A1 | NOVEL CAPSID ASSEMBLY INHIBITORS | AM SCIENCES INC (KR) | 2025-07-24 | — | — | US | disclosed |
| US-20250170121-A1 | ISOQUINOLINONE COMPOUND, AND PREPARATION METHOD AND USE THEREFOR | FUDAN UNIVERSITY (CN) | 2025-05-29 | — | — | US | disclosed |
| EP-4416150-A1 | NOVEL CAPSID ASSEMBLY INHIBITORS | AM Sciences Inc (KR) | 2024-08-21 | — | — | EP | disclosed |
| CN-118159540-A | Novel capsid assembly inhibitor | 南韩商AM科学股份有限公司 | 2024-06-07 | — | — | CN | disclosed |
| WO-2024009283-A1 | AT2 ANTAGONISTS FOR NON-ADDICTIVE PAIN RELIEF | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2024-01-11 | — | — | WO | disclosed |
| CN-116693456-A | Isoquinolinones compound, preparation method and application thereof | 复旦大学 | 2023-09-05 | — | — | CN | disclosed |
| WO-2023160726-A1 | ISOQUINOLINONE COMPOUND, AND PREPARATION METHOD AND USE THEREFOR | 复旦大学 | 2023-08-31 | — | — | WO | disclosed |
| WO-2023063698-A1 | NOVEL CAPSID ASSEMBLY INHIBITORS | AM SCIENCES INC (KR) | 2023-04-20 | — | — | WO | disclosed |
| US-8980903-B2 | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors | AMGEN INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980903-B2 | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors | AMGEN INC. (US) | 2015-03-17 | — | — | US | disclosed |
| CN-1212704-A | Serine protease inhibitors | AKZO NOBEL NV (NL) | 1999-03-31 | — | — | CN | disclosed |
| EP-0886647-A1 | SERINE PROTEASE INHIBITORS | Akzo Nobel N.V. (NL) | 1998-12-30 | — | — | EP | disclosed |
| CN-1202902-A | Thrombin inhibitors | AKZO NOBEL NV (NL) | 1998-12-23 | — | — | CN | disclosed |
| WO-1998047876-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | AKZO NOBEL N.V. (NL) | 1998-10-29 | — | — | WO | disclosed |
| EP-0858464-A1 | THROMBIN INHIBITORS | Akzo Nobel N.V. (NL) | 1998-08-19 | — | — | EP | disclosed |
| WO-1997031937-A1 | SERINE PROTEASE INHIBITORS | AKZO NOBEL N.V. (NL) | 1997-09-04 | — | — | WO | disclosed |
| WO-1997031939-A1 | SERINE PROTEASE INHIBITORS | AKZO NOBEL N.V. (NL) | 1997-09-04 | — | — | WO | disclosed |
| WO-1997030073-A1 | SERINE PROTEASE INHIBITORS | AKZO NOBEL N.V. (NL) | 1997-08-21 | — | — | WO | disclosed |
| WO-1997017363-A1 | THROMBIN INHIBITORS | AKZO NOBEL N.V. (NL) | 1997-05-15 | — | — | WO | disclosed |
| EP-0640594-A1 | Hydantoin derivative as metalloprotease inhibitor | FUJIREBIO INC. (JP) | 1995-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250235462-A1 | NOVEL CAPSID ASSEMBLY INHIBITORS | ZC3HAV1, GTF3C3, ZC3HAV1L | EPHX2 4025/4885NPSR1 4367/4885KDM4E 1998/4885 |
| US-20250170121-A1 | ISOQUINOLINONE COMPOUND, AND PREPARATION METHOD AND USE THEREFOR | FABP5, FABP4, FABP1 | EPHX2 3520/4885NPSR1 3565/4885KDM4E 2494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.